Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Edwards Lifesciences ( (EW) ).
On July 21, 2025, Edwards Lifesciences announced that Larry L. Wood will resign from his role as Corporate Vice President and Group President, effective September 1, 2025, to pursue a senior leadership position outside the cardiovascular sector. Daniel J. Lippis, currently the Corporate Vice President for Japan, Greater China, and Asia Pacific, will assume responsibility for the Transcatheter Aortic Valve Replacement division, potentially impacting the company’s strategic direction in this area.
The most recent analyst rating on (EW) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
Edwards Lifesciences presents a strong financial foundation with significant growth in certain segments and strategic advancements. However, high valuation, mixed technical indicators, and potential challenges from tariffs and acquisitions balance the positive aspects, resulting in a moderate overall score.
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
Edwards Lifesciences is a company operating in the medical technology industry, primarily focusing on products and services related to heart valve therapies and critical care monitoring. The company is known for its innovations in transcatheter aortic valve replacement and surgical structural heart solutions.
Average Trading Volume: 4,131,563
Technical Sentiment Signal: Hold
Current Market Cap: $44.46B
See more data about EW stock on TipRanks’ Stock Analysis page.